Believe

Achieve

History


2016

  • Regulus Announces Two New Drug Development Candidates | December 6, 2016
  • Regulus Reports Positive Top-line Data | June 7, 2016
  • Regulus Expands Clinical Trial Collaboration with GlaxoSmithKline | June 1, 2016
  • RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up | Feb 17, 2016
  • Regulus Completes RG-101 Enrollment in Phase II Combination Study | Jan 21, 2016

2015

  • RG-125(AZD4076) enters Phase I clinical development | December 18, 2015
  • Regulus expands development of RG-101 through clinical trial collaboration with GlaxoSmithKline | November 3, 2015
  • Regulus achieves all research milestones in collaboration with Biogen to identify microRNA biomarkers for multiple sclerosis | October 28, 2015
  • Regulus initiates dosing in a first-in- human Phase I clinical study of RG-012 | June 4, 2015
  • Regulus announces selection by AstraZeneca of third clinical candidate, RG-125, a GalNAc-conjugated anti-miR targeting miR-103/107 for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes | May 7, 2015

2014

  • Regulus announces closing of public offering of $103.5M of common stock | November 3, 2014
  • Regulus announces demonstration of human proof-of- concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101 for the treatment of hepatitis C virus infection | October 22, 2014
  • Regulus initiates ATHENA natural history of disease study in Alport syndrome patients | September 18, 2014
  • Regulus enters into new collaboration agreement with Biogen Idec to identify microRNA biomarkers in multiple sclerosis | August 5, 2014
  • Regulus receives orphan drug designation for RG-012, an anti-miR targeting miR-21, for the treatment of Alport syndrome | July 21, 2014
  • Regulus announces initiation of dosing in the Phase I clinical study of RG-101 | May 8, 2014

2013

  • Regulus announces addition to NASDAQ biotechnology index | December 23, 2013
  • Regulus receives milestone payment from Biogen Idec for progress in microRNA biomarkers multiple sclerosis collaboration | November 20, 2013
  • Regulus and AstraZeneca select a new microRNA oncology target under strategic alliance | October 28, 2013
  • Regulus announces selection of first clinical candidate, RG-101, a GalNAc-conjugated anti-miR targeting miR-122 for the treatment of hepatitis C infection | August 13, 2013
  • Regulus announces $49.2M in total gross proceeds from public offering | July 23, 2013

2012

  • Regulus announces addition to Russell 2000 Index | December 20, 2012
  • Regulus announces $80.9M in total gross proceeds from IPO and other financial transactions | November 5, 2012
  • Regulus announces pricing of initial public offering and begins trading on the NASDAQ Global Market under the symbol “RGLS.” | October 4, 2012
  • Regulus and Biogen Idec form collaboration to explore microRNA biomarkers for disease monitoring and response to therapy | August 15, 2012
  • Regulus forms strategic alliance for discovery, development and commercialization of microRNA therapeutics with AstraZeneca | August 4, 2012

2011

  • Regulus initiates an orphan and rare disease microRNA therapeutic effort in brain cancer | December 12, 2011
  • Regulus and GlaxoSmithKline name a third alliance microRNA target triggering a preclinical milestone payment | July 20, 2011

2010

  • sanofi-aventis completes $10 million equity investment in Regulus | October 28, 2010
  • Regulus and sanofi-aventis form major strategic alliance on microRNA therapeutics | June 22, 2010
  • Regulus and GlaxoSmithKline establish new collaboration to develop and commercialize microRNA therapeutics targeting miR-122 | February 25, 2010

2009

  • Regulus achieves initial milestone in its inflammatory diseases collaboration with GlaxoSmithKline | May 14, 2009
  • Regulus receives $20 million in a series A equity financing | March 4, 2009
  • Regulus completes conversion from LLC to C-corporation | January 2, 2009

2008

  • Regulus named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top privately held biotech companies of 2008 | June 24, 2008
  • Regulus and GlaxoSmithKline form strategic alliance to develop microRNA-targeted therapeutics to treat inflammatory diseases | April 17, 2008

2007

  • Regulus is launched as a joint venture between Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. to discover, develop and commercialize microRNA therapeutics | September 7, 2007